Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
JMIR Research Protocols|September 14, 2016
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell AnemiaAngela E Rankine-Mullings, Courtney R Little, Marvin E Reid, et al.
Pediatric Blood & Cancer|February 2, 2012
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemiaOfelia Alvarez, Scott T Miller, Winfred C Wang, et al.
JMIR Research Protocols|September 4, 2025
The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled TrialTanisha D Belton, Caren M Steinway, Olivia Teng, et al.
Health Care Transitions|March 23, 2026
Recruitment and retention of young adults with sickle cell diseaseTanisha Belton, Lane Carbaugh, Evelyn Stevens, et al.
The Journal of Pediatrics|November 3, 2009
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trialRussell E Ware, Renee C Rees, Sharada A Sarnaik, et al.
The Journal of Infectious Diseases|August 29, 2024
Circulating immune complexes and G6PD deficiency predict readmissions for blackwater fever and severe anemia in children with severe malaria in Eastern UgandaRuth Namazzi, Kagan A Mellencamp, Robert O Opoka, et al.
Nature Genetics|July 16, 2002
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly)Katrin Hoffmann, Christine K Dreger, Ada L Olins, et al.
The New England Journal of Medicine|December 13, 2021
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell DiseaseJulie Kanter, Mark C Walters, Lakshmanan Krishnamurti, et al.
Lancet (London, England)|December 17, 2015
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E Ware, Barry R Davis, William H Schultz, et al.
British Journal of Haematology|October 15, 2024
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan AfricaCatherine I Segbefia, Luke R Smart, Susan E Stuber, et al.
Pageof 27